3 ⅐ No. 2 Genetic testing for breast cancer: Where are health care providers in the decision process? Christine M. Velicer, MS1,2, and Stephen Taplin, MD, MPH2,3 Purpose: To identify BRCA1/2 knowledge, genetic testing intentions, and communication patterns in breast cancer survivors (...
On May 14, 2013 Angelina Jolie [2013] revealed that she has a deleterious BRCA1 gene mutation associated with hereditary breast and ovarian cancer (HBOC) and on June 13, the Supreme Court ruled that human genes are not patentable [Kesselheim et al., 2013]. While BRCA gene testing has ...
Methods for the detection ofBRCA1andBRCA2pathogenic mutations are now widely accessible. Until now, the principal aim ofBRCA1/2pathogenic mutation testing has been to enable risk assessment to permit early diagnosis and cancer prevention. However, it is increasingly apparent that knowledge ofBRCAstatu...